TITLE

Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat

AUTHOR(S)
Chaput, J.-P.; St-Pierre, S.; Tremblay, A.
PUB. DATE
January 2007
SOURCE
Mini Reviews in Medicinal Chemistry;Jan2007, Vol. 7 Issue 1, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The currently available drugs for long-term treatment of obesity are sibutramine and orlistat. They have been shown to be able to induce significant weight loss, with important co-morbidity reduction, allowing the maintenance of reduced body weight for at least 1-2 years. Cardiostimulating and gastrointestinal adverse effects are however not negligible.
ACCESSION #
23561716

 

Related Articles

  • Safety of drug therapies used for weight loss and treatment of obesity. Ioannides-Demos, Lisa L.; Proietto, Joseph; Tonkin, Andrew M.; McNeil, John J. // Drug Safety;2006, Vol. 29 Issue 4, p277 

    Some of the medications used for weight loss in the management of obesity have been associated with unacceptable morbidity and mortality. Safety concerns have led to the withdrawal of aminorex, followed by the fenfluramines in 1997, and phenylpropanolamine (norephedrine) in 2000. Aminorex was...

  • Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity. Farina, Maria; Baratta, Roberto; Nigro, Angela; Vinciguerra, Federica; Puglisi, Concetta; Schembri, Roberto; Virgilio, Clara; Vigneri, Riccardo; Frittitta, Lucia // Obesity Surgery;Apr2012, Vol. 22 Issue 4, p565 

    Background: Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes...

  • Choosing the Right Weight Loss Medication for Your Patient Requires Careful Consideration. Still, Christopher // Bariatric Times;Dec2015, Vol. 12 Issue 12, p3 

    The author discusses how to match a patient with the right weight loss medication given his risk, medical history and preferences. He cites the 5 Food and Drug Administration (FDA) approved pharmacotherapy options for treating obesity including phentermine, orlistat and phentermine/topiramate...

  • Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities. Sangmi Oh; Koon Soon Kim; Young Sun Chung; Minho Shong; Seung Bum Park // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p466 

    In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the...

  • New drug policy in childhood obesity. Molnár, D. // International Journal of Obesity;Sep2005 Supplement 2, Vol. 29, pS62 

    OBJECTIVE:To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity.METHODS:The paper reviews current and investigational antiobesity drugs.RESULTS:At present, there are only few drugs approved by the Food and Drug...

  • DRUGS FOR OBESITY. Mead, Mike // Practice Nurse;9/10/2004, Vol. 28 Issue 4, p64 

    Focuses on prescription drugs available to help obese patients to lose weight. Clinical indications of Sibutramine and Orlistat; Contraindications and side effects of the drugs; Importance of monitoring patients who are taking drug therapy.

  • Pharmacotherapy for obesity in menopausal women. Samat, Ashish; Rahim, Asad; Barnett, Anthony // Menopause International;Jun2008, Vol. 14 Issue 2, p57 

    Weight gain, during and after the menopause is common. Contributing factors include ethnicity, reduced physical activity, reduced lean mass, reduced resting metabolic rate and treatment with certain drugs, e.g. steroids, insulin, glitazones. Excess body weight increases the risk of medical...

  • Pharmacotherapy of Childhood Obesity. Freemark, Michael // Diabetes Care;Feb2007, Vol. 30 Issue 2, p395 

    The article presents an analysis of the benefits of lifestyle intervention and pharmacotherapy to the treatment of obesity in adults and children. It cites the role of biological factors in the difficulty of losing weight. Several placebo-controlled studies performed in obese adults showed that...

  • Track 5b: Management - pharmacotherapy.  // International Journal of Obesity & Related Metabolic Disorders;May2004 Supplement, Vol. 28, pS152 

    Presents several abstracts on pharmacotherapy. "Orlistat for the Treatment of Obesity: Cost Utility Model," by David Foxcroft; "Interactive Weight Loss Program--A Possible Tool for Obesity Management in Primary Care," by Judit Gonczi; "Changes of Lifestyle With Sibutramine for Grade II-III Obese...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics